ACADIA Pharmaceuticals Inc (ACAD)
15.03
+0.12
(+0.80%)
USD |
NASDAQ |
Jun 17, 14:54
ACADIA Pharmaceuticals Enterprise Value: 1.993B for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 1.993B |
| June 13, 2024 | 2.023B |
| June 12, 2024 | 2.069B |
| June 11, 2024 | 2.013B |
| June 10, 2024 | 1.988B |
| June 07, 2024 | 1.990B |
| June 06, 2024 | 2.057B |
| June 05, 2024 | 2.061B |
| June 04, 2024 | 2.082B |
| June 03, 2024 | 2.054B |
| May 31, 2024 | 2.024B |
| May 30, 2024 | 2.008B |
| May 29, 2024 | 1.945B |
| May 28, 2024 | 2.023B |
| May 24, 2024 | 2.041B |
| May 23, 2024 | 2.097B |
| May 22, 2024 | 2.143B |
| May 21, 2024 | 2.052B |
| May 20, 2024 | 2.024B |
| May 17, 2024 | 1.973B |
| May 16, 2024 | 1.983B |
| May 15, 2024 | 2.028B |
| May 14, 2024 | 1.985B |
| May 13, 2024 | 2.038B |
| May 10, 2024 | 2.049B |
| Date | Value |
|---|---|
| May 09, 2024 | 2.042B |
| May 08, 2024 | 2.360B |
| May 07, 2024 | 2.380B |
| May 06, 2024 | 2.338B |
| May 03, 2024 | 2.346B |
| May 02, 2024 | 2.351B |
| May 01, 2024 | 2.346B |
| April 30, 2024 | 2.290B |
| April 29, 2024 | 2.354B |
| April 26, 2024 | 2.290B |
| April 25, 2024 | 2.224B |
| April 24, 2024 | 2.270B |
| April 23, 2024 | 2.295B |
| April 22, 2024 | 2.336B |
| April 19, 2024 | 2.304B |
| April 18, 2024 | 2.345B |
| April 17, 2024 | 2.365B |
| April 16, 2024 | 2.347B |
| April 15, 2024 | 2.316B |
| April 12, 2024 | 2.357B |
| April 11, 2024 | 2.401B |
| April 10, 2024 | 2.454B |
| April 09, 2024 | 2.523B |
| April 08, 2024 | 2.466B |
| April 05, 2024 | 2.500B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.654B
Minimum
Jun 21 2022
8.384B
Maximum
Dec 01 2020
4.019B
Average
3.439B
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 18.94B |
| Cassava Sciences Inc | 821.92M |
| Vertex Pharmaceuticals Inc | 113.88B |
| Cormedix Inc | 200.86M |
| Oragenics Inc | 6.996M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.56M |
| Revenue (Quarterly) | 205.83M |
| Total Expenses (Quarterly) | 190.62M |
| EPS Diluted (Quarterly) | 0.10 |
| Gross Profit Margin (Quarterly) | 88.85% |
| Profit Margin (Quarterly) | 8.04% |
| Earnings Yield | -0.07% |
| Normalized Earnings Yield | -0.0666 |